Salmeterol xinafoate

Known as: Salmeterol Xinafoate [Chemical/Ingredient], Xinafoate, Salmeterol 
A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2018
051019922018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
The purpose of this study was to characterise the role of agglomeration on salmeterol xinafoate (SX) dispersion from mixtures for… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
STUDY OBJECTIVE To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. DESIGN A 28-week… (More)
  • table 1
  • table 2
  • table 3
  • table 5
  • table 7
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages… (More)
Is this relevant?
2001
2001
Purpose. To characterize two polymorphs of salmeterol xinafoate (SX-I and SX-II) produced by supercritical fluid crystallization… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table I
Is this relevant?
Highly Cited
1999
Highly Cited
1999
STUDY OBJECTIVES To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1997
Highly Cited
1997
The objectives of this study were to compare the efficacy and safety of salmeterol xinafoate (50 and 100 microg b.i.d.) with that… (More)
Is this relevant?
1995
1995
BACKGROUND Current UK and international guidelines on asthma management recommend that, in pediatric patients still symptomatic… (More)
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Guidelines on asthma management recommend that in patients who still have symptoms on treatment with low-dose inhaled… (More)
Is this relevant?
1994
1994
OBJECTIVE To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with… (More)
Is this relevant?
1992
1992
The effect of inhaled salmeterol xinafoate, a long acting beta 2 agonist, on exercise induced asthma was studied in a double… (More)
Is this relevant?